The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

He joined The Verge in 2019 after nearly two years at Techmeme. Samsung and Google are partnering up to build AR glasses, Samsung’s TM Roh told Bloomberg. But there aren’t many other specifics ...

The nasal spray Spravato, which is made from the drug esketamine, had been approved in 2019 for patients who failed to respond to at least two oral antidepressants. However, it had to be used in ...

Both of those companies have products in various stages of development but have yet to fully deliver on a practical pair of glasses that are actually wearable (and affordable). Meta's Orion ...

Meta is continuing to expand into the AR space after its successful Ray-Ban Meta glasses, as a new report states the company is looking into "real" AR glasses — codenamed "Artemis." Bloomberg's ...

And seeing is what I did with the CaddieVision AR glasses specifically designed for golfers. They're currently available on Indiegogo for pre-order, but at the PGA Show 2025 this week, I went ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

Jan. 21 (UPI) --The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato has been approved to treat a ...

NEW YORK (PIX11) – A nose spray has been approved by the U.S. Food and Drug Administration to help treat depression, Johnson & Johnson announced on Tuesday. Spravato is a first-of-its-kind ...